APS vs. HBP, EMH, COV, PMN, DMT, MBX, IBT, ACST, LTY, and GSD
Should you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include Helix BioPharma (HBP), Emerald Health Therapeutics (EMH), Covalon Technologies (COV), ProMIS Neurosciences (PMN), Small Pharma (DMT), Microbix Biosystems (MBX), IBEX Technologies (IBT), Acasti Pharma (ACST), Liberty Biopharma (LTY), and Devonian Health Group (GSD). These companies are all part of the "biotechnology" industry.
Helix BioPharma (TSE:HBP) and Aptose Biosciences (TSE:APS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, community ranking, media sentiment and dividends.
Helix BioPharma is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.
Aptose Biosciences' return on equity of 0.00% beat Helix BioPharma's return on equity.
Aptose Biosciences received 146 more outperform votes than Helix BioPharma when rated by MarketBeat users. Likewise, 72.11% of users gave Aptose Biosciences an outperform vote while only 63.46% of users gave Helix BioPharma an outperform vote.
In the previous week, Aptose Biosciences had 2 more articles in the media than Helix BioPharma. MarketBeat recorded 2 mentions for Aptose Biosciences and 0 mentions for Helix BioPharma. Helix BioPharma's average media sentiment score of 0.20 beat Aptose Biosciences' score of 0.00 indicating that Aptose Biosciences is being referred to more favorably in the news media.
Helix BioPharma has a beta of -0.78, suggesting that its share price is 178% less volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500.
7.5% of Aptose Biosciences shares are owned by institutional investors. 20.5% of Helix BioPharma shares are owned by company insiders. Comparatively, 19.1% of Aptose Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Aptose Biosciences beats Helix BioPharma on 8 of the 12 factors compared between the two stocks.
Get Aptose Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for APS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aptose Biosciences Competitors List
Related Companies and Tools
Free APS Stock Alerts